SI-B003 + Izalontamab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Dec 2022: Trial registered, NCT05668858
  2. 10 Feb 2023: Trial started, NCT05668858

The trials

NCT05668858: A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

State
Under way
Phase
Phase 1 and Phase 2
People
70 taking part
Started
10 Feb 2023
Primary completion
Dec 2026
Arms
Study treatment
Results
None posted
  1. 30 Dec 2022: Trial registered
  2. 10 Feb 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.